Vertex Pharmaceuticals Inc (VRTX)
Drugs • Health Care
August 03, 2026 Vertex Pharmaceuticals Reports Strong Q2 2026 Financial Results and Raises Revenue Guidance Vertex Pharmaceuticals announced strong Q2 2026 results with revenues of $3.33 billion, a 12% year-over-year increase. The company raised its full-year revenue guidance, driven by growth in cystic fibrosis treatments and the launch of new therapies. Vertex's strategic expansion into additional therapeutic areas positions it for continued success.
July 07, 2026 Vertex Pharmaceuticals Set to Reveal Q2 2026 Financial Results Vertex Pharmaceuticals is set to disclose its Q2 2026 financial results on August 3, followed by a conference call for stakeholders. The company remains a leader in biotech, focusing on innovative therapies for serious diseases.
July 06, 2026 Vertex Pharmaceuticals Enters Definitive Agreement to Acquire Crinetics Pharmaceuticals Vertex Pharmaceuticals has announced a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at strengthening its focus on rare endocrine diseases. This strategic move includes leveraging Crinetics' innovative treatments like PALSONIFY and atumelnant, which promise to revolutionize care for acromegaly and congenital adrenal hyperplasia.
July 01, 2026 Vertex Pharmaceuticals Secures FDA Approval for Expanded Use of CASGEVY® in Treating Sickle Cell Disease and Beta Thalassemia Vertex Pharmaceuticals has received FDA approval for CASGEVY®, allowing treatment of sickle cell disease and beta thalassemia in children aged two and older. This gene therapy offers new hope for patients with limited treatment options, enhancing their quality of life and reducing hospital visits.
June 05, 2026 Vertex Pharmaceuticals Unveils Promising ALYFTREK® Data at European Cystic Fibrosis Conference Vertex Pharmaceuticals presented promising data on ALYFTREK® at the European Cystic Fibrosis Conference, highlighting improved CF treatment for children aged 2-5. The study shows significant reductions in sweat chloride levels, paving the way for regulatory submissions and expanding treatment options for young patients.
June 03, 2026 Vertex Pharmaceuticals to Showcase Leadership at Goldman Sachs Healthcare Conference Vertex Pharmaceuticals will present at the Goldman Sachs Healthcare Conference on June 10, 2026. Dr. Reshma Kewalramani will lead a discussion on the company’s innovative therapies and clinical pipeline, emphasizing its commitment to transforming medicine for serious diseases.
June 01, 2026 Vertex Pharmaceuticals Secures FDA Acceptance for Povetacicept in IgA Nephropathy Vertex Pharmaceuticals has received FDA acceptance for its BLA for povetacicept, aimed at treating IgA nephropathy. The Phase 3 RAINIER trial showed promising results, and a commercial launch is anticipated by November 2026, marking a potential breakthrough in nephrology.
May 06, 2026 Vertex Pharmaceuticals Secures Reimbursement Agreement for CASGEVY® in Germany Vertex Pharmaceuticals has announced a significant reimbursement agreement for CASGEVY®, its CRISPR gene therapy for sickle cell disease and beta thalassemia, in Germany. This marks a crucial step towards sustainable access for patients, highlighting Vertex's commitment to improving health outcomes globally.
May 05, 2026 Vertex Pharmaceuticals Inc. Reports Strong Q1 2026 Financial Performance Vertex Pharmaceuticals reported impressive financial growth in Q1 2026, with revenues reaching $2.98 billion and net income at $1.03 billion. Key advancements in cystic fibrosis therapies and ongoing pipeline developments reinforce its position in the biotechnology sector.
May 04, 2026 Vertex Pharmaceuticals Inc. Reports Strong Q1 2026 Financial Results Vertex Pharmaceuticals has announced robust Q1 2026 financial results, achieving $2.99 billion in revenue, an 8% increase year-over-year. The growth is largely attributed to successful cystic fibrosis therapies and the launch of new products CASGEVY and JOURNAVX. The company anticipates continued revenue growth throughout 2026.
April 06, 2026 Vertex Pharmaceuticals Set to Announce First Quarter 2026 Financial Results Vertex Pharmaceuticals is set to release its Q1 2026 financial results on May 4, 2026, with a conference call to discuss its performance and future outlook. The company is renowned for its commitment to innovation in biotechnology and employee satisfaction.
April 01, 2026 Vertex Pharmaceuticals Secures FDA Approval for ALYFTREK® and TRIKAFTA® Label Extensions Vertex Pharmaceuticals has secured FDA approval for label extensions of ALYFTREK and TRIKAFTA, expanding treatment options for cystic fibrosis patients. This advancement allows approximately 95% of individuals diagnosed with CF in the U.S. to access these innovative therapies, significantly enhancing quality of life.
March 09, 2026 Vertex Pharmaceuticals Reports Positive Interim Results for Povetacicept in IgA Nephropathy Trial Vertex Pharmaceuticals has announced positive interim results from the Phase 3 RAINIER trial for povetacicept, demonstrating significant efficacy in reducing urine protein levels in IgA nephropathy patients. The treatment shows a favorable safety profile and could lead to accelerated FDA approval, offering hope for improved kidney disease management.
March 05, 2026 Vertex Pharmaceuticals Announces Participation in Upcoming Investor Conferences Vertex Pharmaceuticals will participate in two significant investor conferences in March 2026, showcasing its commitment to transparency and innovation. The company aims to provide insights into its strategic initiatives and robust clinical pipeline for transformative therapies.
March 05, 2026 Vertex Pharmaceuticals Unveils Promising Data on JOURNAVX® for Pain Management Vertex Pharmaceuticals has reported groundbreaking findings from a Phase 4 study of JOURNAVX® (suzetrigine), a non-opioid pain signal inhibitor. The study revealed a 90.9% opioid-free recovery rate in patients post-surgery, highlighting JOURNAVX's potential in transforming pain management and reducing opioid dependency.
February 17, 2026 Vertex Pharmaceuticals to Participate in TD Cowen Health Care Conference Vertex Pharmaceuticals will participate in the TD Cowen Health Care Conference on March 3, 2026, featuring a discussion led by CEO Reshma Kewalramani. The company aims to share insights on its strategic direction and innovative therapies targeting serious diseases.
February 13, 2026 Vertex Pharmaceuticals Inc. Reports Strong Financial Performance in 2025 Vertex Pharmaceuticals Inc. reported impressive financial results for 2025, with revenues reaching $12 billion, driven by strong product performance and strategic market expansion. The company continues to invest in R&D while maintaining a robust balance sheet, positioning itself well for future growth in the biotechnology sector.
February 12, 2026 Vertex Pharmaceuticals Reports Impressive Financial Results for Q4 and Full Year 2025 Vertex Pharmaceuticals announced strong Q4 and full-year 2025 financial results, showcasing a 10% revenue increase to $3.19 billion in Q4. The company is poised for continued growth in 2026, particularly in cystic fibrosis therapies and new product launches.
January 20, 2026 Vertex Pharmaceuticals Set to Release Q4 and Full Year 2025 Financial Results Vertex Pharmaceuticals will announce its Q4 and full year 2025 financial results on February 12, 2026, with a conference call for stakeholders. The company continues to focus on innovative therapies and maintaining a strong workplace culture.
January 11, 2026 Vertex Pharmaceuticals Inc. Updates Pipeline and Business Strategy Ahead of Investor Meetings Vertex Pharmaceuticals has announced key updates on its business strategy and clinical pipeline ahead of investor meetings. Highlights include advancements in treatments for cystic fibrosis and sickle cell disease, as well as a focus on expanding its commercial reach and therapeutic offerings for 2026.
December 22, 2025 Vertex Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Vertex Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its innovations in biopharmaceuticals. Dr. Reshma Kewalramani will highlight the company’s commitment to developing transformative therapies for serious diseases. The presentation will be available via live webcast for wider access.
November 19, 2025 Vertex Pharmaceuticals to Feature at Citi’s 2025 Global Healthcare Conference Vertex Pharmaceuticals will participate in Citi’s 2025 Global Healthcare Conference on December 3, discussing their biotech advancements and strategic plans. Key leaders will engage in discussions about ongoing research and a diverse clinical pipeline targeting serious health conditions.
November 08, 2025 Vertex Pharmaceuticals Unveils Promising Phase 1/2 Data for Povetacicept at ASN Kidney Week 2025 Vertex Pharmaceuticals presented encouraging Phase 1/2 data for povetacicept at ASN Kidney Week 2025, highlighting significant reductions in proteinuria and stable kidney function in patients with IgA nephropathy and primary membranous nephropathy. The drug has received FDA Breakthrough Therapy Designation, expediting its path to market.
November 04, 2025 Vertex Pharmaceuticals Inc. Reports Strong Q3 2025 Financial Results Vertex Pharmaceuticals Inc. reported $3.07 billion in net product revenues for Q3 2025, marking a 10.9% increase year-over-year. The company continues to innovate in cystic fibrosis and sickle cell disease, despite facing reimbursement challenges.
October 27, 2025 Vertex Pharmaceuticals to Showcase Leadership at UBS Global Healthcare Conference Vertex Pharmaceuticals will have its CEO Reshma Kewalramani speaking at the UBS Global Healthcare Conference on November 11, 2025. The company is known for its innovative medicines and a strong clinical pipeline, underlining its commitment to addressing serious medical conditions.
October 17, 2025 Vertex Pharmaceuticals Announces Significant Progress in Povetacicept Development Vertex Pharmaceuticals has made major advancements in povetacicept, an investigational therapy for IgA nephropathy and primary membranous nephropathy. With Breakthrough Therapy Designation from the FDA and pivotal trials underway, the company aims to transform treatment options for patients.
October 06, 2025 Vertex Pharmaceuticals to Reveal Q3 2025 Financial Results Vertex Pharmaceuticals is set to announce its Q3 2025 financial results on November 3, 2025. The company continues to lead in biotechnology with innovative therapies and a strong commitment to research, while also preparing for a conference call to discuss the results.
September 25, 2025 Vertex Pharmaceuticals Announces Significant Advances in Kidney Disease Portfolio Vertex Pharmaceuticals has made significant strides in its kidney disease portfolio, securing Breakthrough Therapy Designation for povetacicept in IgAN and completing enrollment for inaxaplin in AMKD. Additionally, the launch of the AGLOW trial for VX-407 in ADPKD marks a commitment to innovative therapies for serious kidney conditions.
September 23, 2025 Vertex Pharmaceuticals Partners with Jayson Tatum to Promote Non-Opioid Pain Management Vertex Pharmaceuticals has partnered with Jayson Tatum to promote JOURNAVX, a groundbreaking non-opioid pain management solution. Tatum shares his personal recovery story, highlighting the importance of exploring alternatives to opioids for acute pain relief.
August 05, 2025 Vertex Pharmaceuticals Inc. Reports Strong Q2 2025 Financial Results Vertex Pharmaceuticals Inc. reports impressive Q2 2025 results, showcasing $2.96 billion in revenue and a net income of $1.03 billion. The growth stems from successful product launches and a strong focus on innovation, especially in cystic fibrosis and pain management.
May 06, 2025 Vertex Pharmaceuticals Inc. Reports Strong Q1 2025 Performance Amid Strategic Developments Vertex Pharmaceuticals Inc. reported a solid Q1 2025 with revenues of $2.77 billion, driven by strong sales of TRIKAFTA and ALYFTREK. Despite a decline in net income due to increased R&D expenses, the company remains focused on expanding its product pipeline and strategic collaborations.
May 05, 2025 Vertex Pharmaceuticals Reports Strong Q1 2025 Financial Results Vertex Pharmaceuticals reported $2.77 billion in Q1 2025 revenues, up 3% year-over-year. The company raised its revenue guidance and continues to advance its cystic fibrosis and pain management therapies, positioning itself for continued growth.
April 11, 2025 Vertex Pharmaceuticals: A Landmark Achievement in Cystic Fibrosis Research Vertex Pharmaceuticals celebrates Dr. Paul Negulescu, awarded the 2025 Canada Gairdner International Award for his groundbreaking work in cystic fibrosis research. His leadership has led to the development of innovative therapies that significantly improve patient outcomes and redefine CF treatment.
April 07, 2025 Vertex Pharmaceuticals Expands KAFTRIO® Indication in Europe: A Milestone for Cystic Fibrosis Patients Vertex Pharmaceuticals has received European Commission approval to expand the use of KAFTRIO® for cystic fibrosis patients aged 2 and older with non-class I mutations. This pivotal approval improves access to life-changing treatments across Europe, reflecting Vertex's commitment to innovation in healthcare.
April 07, 2025 Vertex Pharmaceuticals Set to Release First Quarter 2025 Financial Results Vertex Pharmaceuticals is set to release its Q1 2025 financial results on May 5, 2025. A conference call will follow at 4:30 PM ET, providing insights into the company's performance and future strategies.
March 28, 2025 Vertex Pharmaceuticals Updates Type 1 Diabetes Portfolio: Key Developments Announced Vertex Pharmaceuticals announced key updates on its Type 1 Diabetes portfolio, focusing on VX-264 and Zimislecel. Despite VX-264 not meeting efficacy endpoints, Zimislecel shows promise with ongoing trials and potential regulatory submissions by 2026.
March 21, 2025 SWOT Analysis of Vertex Pharmaceuticals Inc. in 2025 This SWOT analysis examines Vertex Pharmaceuticals Inc.'s strategic position in 2025, highlighting its strengths in innovative therapies and R&D, while addressing weaknesses and market threats. The analysis also explores potential growth opportunities in new therapeutic areas and global markets.
March 07, 2025 Vertex Pharmaceuticals Secures UK MHRA Approval for ALYFTREK®: A Game-Changer for Cystic Fibrosis Treatment Vertex Pharmaceuticals has received UK MHRA approval for ALYFTREK®, a new once-daily therapy for cystic fibrosis patients with certain CFTR gene mutations. This treatment improves CFTR protein function and aims to enhance the quality of life for CF patients. Vertex is collaborating with healthcare authorities to ensure swift access for eligible patients.
February 28, 2025 Vertex Pharmaceuticals Secures Positive CHMP Opinion for KAFTRIO® Label Expansion Vertex Pharmaceuticals has announced a positive opinion from the CHMP for KAFTRIO®'s label expansion, which aims to include more cystic fibrosis patients. This development could provide thousands of individuals with access to life-changing treatments that target the underlying causes of CF.
February 18, 2025 Vertex Pharmaceuticals to Showcase Leadership Insights at Upcoming Investor Conferences Vertex Pharmaceuticals will participate in three major investor conferences in March 2025, showcasing insights from its executive team. The company will provide live webcasts, ensuring stakeholders can engage with its innovative strategies and ongoing commitment to biopharmaceutical excellence.
February 13, 2025 Vertex Pharmaceuticals Inc. Reports Strong Performance in 2024 Annual Report Vertex Pharmaceuticals Inc. reported a strong performance in its 2024 annual report, highlighting a 12% revenue growth driven by TRIKAFTA. Despite a net loss, the company made significant advancements in product approvals and R&D investments, positioning itself for future growth in the biotech sector.
February 10, 2025 Vertex Pharmaceuticals Reports Robust Financial Results for Q4 and Full Year 2024 Vertex Pharmaceuticals has announced strong financial results for Q4 and full year 2024, driven by a 16% increase in product revenue. The company is set for growth in 2025 with new CF treatments and a robust clinical pipeline, despite facing some operational challenges.
November 05, 2024 Vertex Pharmaceuticals Inc. Reports Strong Q3 2024 Financial Results Vertex Pharmaceuticals Inc. showcased robust Q3 2024 results, with revenues reaching $2.77 billion and a net income of $1.04 billion. The company continues to invest in its R&D pipeline, focusing on innovative therapies for serious diseases like cystic fibrosis and sickle cell disease.
August 02, 2024 Vertex Pharmaceuticals Inc. Reports Q2 2024 Financial Results: A Transformative Period Vertex Pharmaceuticals reported Q2 2024 financial results, highlighting a significant net loss despite a 6% increase in revenue. The company's focus on R&D and new product launches reflects its commitment to innovation in biotechnology.
May 07, 2024 Vertex Pharmaceuticals Inc. Reports Robust Q1 2024 Financial Results Vertex Pharmaceuticals Inc. reported a net income of $1.3 billion for Q1 2024, reflecting strong growth driven by its innovative therapies and strategic acquisitions. The company continues to expand its market presence while investing heavily in R&D for future product launches.